Scott Lippe, MD
Gastroenterology · Paramus, NJNPI 1992766844
Payments from drug & device makers
Across 283 payments — averaging $11.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$596
- Bristol Myers Squibb$577
- AbbVie$498
- Takeda Pharmaceuticals U.S.A., Inc.$382
- Medtronic$367
- Johnson & Johnson$182
- plus $703 from 23 others
What the payments were for
- Speaking & faculty fees$2758%
- Food & beverage$3,03092%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 60 | $596 |
| Bristol Myers Squibb | 91 | $577 |
| AbbVie(2 entities) | 56 | $498 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $382 |
| Medtronic | 8 | $367 |
| Johnson & Johnson | 12 | $182 |
| Evoke Pharma, Inc. | 6 | $99 |
| Redhill Biopharma Inc. | 6 | $75 |
| Pfizer | 5 | $72 |
| QOL Medical, LLC | 5 | $67 |
| Gilead | 4 | $60 |
| Intercept Pharmaceuticals, Inc. | 3 | $40 |
| Braintree Laboratories, Inc. | 1 | $25 |
| Incyte Corporation | 1 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Merck | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Amgen | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Echosens North America, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GATTEX$275
How this compares
$3,305 in reported general payments places this provider in the 55th percentile of 701 gastroenterology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 26 | $313,378 |
| OzempicSemaglutide | 78 | $118,095 |
| MounjaroTirzepatide | 68 | $98,178 |
| ZenpepLipase/Protease/Amylase | 26 | $97,474 |
| XifaxanRifaximin | 48 | $84,254 |
| Humira PenAdalimumab | 11 | $70,224 |
| EliquisApixaban | 173 | $54,055 |
| JanuviaSitagliptin Phosphate | 108 | $50,516 |
| Risperidone ErRisperidone Microspheres | 37 | $43,378 |
| LinzessLinaclotide | 39 | $35,642 |
| SantylCollagenase Clostridium Hist. | 96 | $30,868 |
| VraylarCariprazine Hcl | 23 | $16,496 |
| JardianceEmpagliflozin | 35 | $14,915 |
| TrulicityDulaglutide | 26 | $13,803 |
| XareltoRivaroxaban | 44 | $12,537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Tresiba, Novolog | $19 | $123,367127 claims |
| Lilly USA, LLCMounjaro, Trulicity | $19 | $111,98194 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $596 | $84,25448 claims |
| PfizerEliquis | $72 | $54,055173 claims |
| AbbVieLinzess, Vraylar | $498 | $52,13962 claims |
| MerckJanuvia | $21 | $50,516108 claims |
| Johnson & JohnsonXarelto | $182 | $12,53744 claims |
| Sanofi-aventis U.S. LLCLantus | $18 | $3,50847 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 701 gastroenterology providers in New Jersey.
Other gastroenterology in Paramus
- Kiran RaoSparta$1.3M
- Adekunle AdeotiIrvington$1.2M
- Carl WallachMorristown$766K
- Vinod RustgiNew Brunswick$697K
- Arvind TrindadeNew Brunswick$652K
- Barry KaufmanEgg Harbor Township$595K
- Promila BanerjeeStratford$522K
- Neil NagariaToms River$442K
- Zamir BrelviNewark$408K
- Adam ElfantMount Laurel$385K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.